A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen — DAS181-2-05

Parainfluenza Clinical Trial

Official title:
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Status Completed

Clinical Trial Summary

This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01644877
Study type	Interventional
Source	Ansun Biopharma, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 2014
Completion date	December 15, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02984280` - Specific Respiratory Infections as Triggers of Acute Medical Events	N/A
Suspended	`NCT00186927` - A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers	Phase 1
Recruiting	`NCT03808922` - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study	Phase 3
Completed	`NCT00641017` - Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine	Phase 1
Completed	`NCT01924793` - An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection	Phase 2